Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling

J Pain
August 2008
https://www.ncbi.nlm.nih.gov/pubmed/18468954

Oxycodone combined with opioid receptor antagonists: efficacy and safety

Expert Opin Drug Saf
May 2013
https://pubmed.ncbi.nlm.nih.gov/23534906/

Introduction: A mu receptor antagonist combined with oxycodone (OXY) may improve pain control, reduce physical tolerance and withdrawal, minimizing opioid-related bowel dysfunction and act as an abuse deterrent.

Proceedings #47: Low Dose Naltrexone: A Viable Alternative for Long Term Chronic Pain?

Brain Stimulation
01 March 2019
https://www.brainstimjrnl.com/article/S1935-861X(18)30634-X/pdf

129 Medication Assisted Treatment Protocol

Cambridge University Press
24 April 2020
https://pubmed.ncbi.nlm.nih.gov/32375158/

Anticonvulsant Effects of Thalidomide on Pentylenetetrazole-Induced Seizure in Mice: A Role for Opioidergic and Nitrergic Transmissions

Epilepsy Res
August 2020
https://pubmed.ncbi.nlm.nih.gov/32447240/?from_term=low+dose+naltrexone&from_sort=date&from_size=100&from_pos=2

Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial

Drug Alcohol Depend
01 June 2018
https://pubmed.ncbi.nlm.nih.gov/29674251/

Pharmacology Update: Low-Dose Naltrexone as a Possible Nonopioid Modality for Some Chronic, Nonmalignant Pain Syndromes

Am J Hosp Palliat Care
October 2019
https://pubmed.ncbi.nlm.nih.gov/30917675/

Very low dose naltrexone in opioid detoxification: a double-blind, randomized clinical trial of efficacy and safety

Toxicol Res
21 November 2019
https://pubmed.ncbi.nlm.nih.gov/32042711/

Opioid-induced hypogonadism: Pathophysiology, clinical and therapeutics review

Clin Exp Pharmacol Physiol
May 2020
https://pubmed.ncbi.nlm.nih.gov/31886562/

Does Naltrexone Treatment Lead to Depression? Findings From a Randomized Controlled Trial in Subjects With Opioid Dependence (Abstract)

J Psychiatry Neurosci
January 2006
https://pubmed.ncbi.nlm.nih.gov/16496034/

Objective: Dysphoria and depression have been cited as side effects of the opioid antagonist naltrexone. We aimed to assess whether depressive symptoms are a clinically relevant side effect in a population receiving naltrexone as a treatment for opioid dependence.